GPT Healthcare Ltd (NSE:GPTHEALTH)

Q1 2027 GPT Healthcare Ltd Earnings Call Transcript

Aug 4, 2026 / 05:30 AM GMT

Release Date Price: ₹162.16 (-1.09%)

Transcript

Key Points

Positve

GPT Healthcare Ltd (NSE:GPTHEALTH) reported strong financial performance in Q1 FY27, with total income increasing by 18.2% and PAT surging by 66% year-over-year.
The company's mature hospitals maintained a healthy occupancy of 58.37% (excluding the new Raipur facility), with flagship ILS Salt Lake and Dum Dum hospitals seeing occupancy improvements to 62% and 65%, respectively.
GPT Healthcare Ltd (NSE:GPTHEALTH) is successfully executing its expansion strategy, with the Raipur hospital ramping up occupancy from 7% to 17% year-over-year and the Jamshedpur project on track for commissioning in Q4 FY27.
The company is advancing its clinical excellence through high-end procedures, including over 800 cumulative robotic surgeries, 700+ renal transplants, and the first liver transplant in Raipur, which is boosting ARPOB and case mix.
GPT Healthcare Ltd (NSE:GPTHEALTH) is pursuing an asset-light model for new hospitals (Raipur and Jamshedpur), reducing real estate investment and supporting its long-term target of 25% ROE/ROCE.
Management expects EBITDA margins to improve by 200 basis points to ~21% for FY27, driven by better occupancy, reduced losses at Raipur, and a favorable specialty mix.

Negative

GPT Healthcare Ltd (NSE:GPTHEALTH) experienced a slight occupancy dip at its Agartala hospital due to geopolitical factors, including tribal elections in Tripura that restricted patient movement for nearly a month.
The newly commissioned Raipur hospital continues to incur losses (Rs. 3 crore in Q1), and its ARPOB declined slightly to Rs. 42,300 due to a temporary reliance on lower-paying Ayushman Bharat patients.
International patient inflows from Bangladesh, particularly at Agartala, have not yet normalized to pre-disruption levels, with management expecting recovery only over the next six months.
The Jamshedpur hospital commissioning is subject to regulatory approvals and could be delayed to the beginning of the next fiscal year if approvals are not received in time.
GPT Healthcare Ltd (NSE:GPTHEALTH) faces higher doctor attrition rates of around 10% in its newer markets like Agartala and Raipur, compared to 6-7% in Kolkata, due to geographic challenges.
The company's growth is partially dependent on evolving markets like Howrah, where patient trust and awareness of corporate healthcare are still being developed, requiring ongoing market education.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GPTH.NS - GPT Healthcare Ltd
Q1 2027 GPT Healthcare Ltd Earnings Call
Aug 04, 2026 / 05:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and Gentlemen, Good day and welcome to GPT Healthcare Limited Q1 FY27 Earnings Conference Call.

As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing then 0 on your touchtone phone.

Please note that this conference is being recorded.

I now hand the conference over to Ms. Pedral Bhattar from MUSG Intime.

Thank you and over to you ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.